The overexpression of EGFR in a variety of human cancers, including head, neck, breast, lung, colorectal, prostate, renal, pancreas, ovary, and brain cancers results in poor treatment outcomes due to resistance to hormone therapy, cytotoxic drugs, and radiotherapy.10,11 As a result, international recommendations advocate anti-EGFR medicines as the first-line treatment in patients with advanced EGFR mutations, due to their higher efficacy and safety compared to standard chemotherapy.9,12,13. This evidence concerns the gene EGFR and brain cancer.